Dr. Cornelius Maas

Partner at SHS Capital - Building European Healthcare Champions

📍 Germany🔄 Updated October 2026💼 7 investments📅 7 years investing🗓 Last invested Aug 2025
VC🌍 Germany
7
Total investments
0
Early stage
3
Mid stage
1
Late stage
7y
Years active

Portfolio

4 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor & Board Observer
Mar 2023
SIMULANDS was founded by a group of renowned clinicians, experienced engineers, entrepreneurs, and industry professionals in the field of Medical Devices and Structural Heart. We seek to revolutionize R&D and Education in the Structural Heart space. Simulators offer solutions that are more practical, cost-effective, and ethical versus traditional animal research practices. The 3R principles (replacement, reduction, and refinement) for more humane animal research are important guiding principles as our industry evolves. The latest technological advancements allow us to focus on what matters most – replicating procedure experiences that provide real tactile responses, and actual procedural imaging guidance with a true understanding of device performance. We believe the role of simulators should evolve from demo tools to complete educational, certification, and recertification platforms. SIMULANDS develops Human Grade platforms that are designed and validated according to all relevant ISO normative requirements. Our simulators are of clinical and technical equivalence to human cardiovascular systems and meet required benchmarks of various competent authorities, ethics committees and notified bodies (CE, FDA, MDR). We create simulators that are tailor-made, beautifully designed, simple to use and highly portable, and our joint training programs cater to a wide range of experience and knowledge levels. Questions? Support@Simulands.com
Investor & Board Observer
May 2022
All primary care services. No waiting time. Always 595,- (NOK)
Investor & Board Observer
Jan 2020
Selfapy is the first digital self-help solution on prescription against depression and anxiety.
Investor & Board Observer
Jan 2019
​evitria is specialized in CHO-based transient expression of antibodies (including bispecific and fusion antibodies). With a track record of more than 120,000 successful antibody production runs for our clients, we can offer fast and reliable project execution at high quality standards (all production facilities in Switzerland) and affordable prices. Transfections are made with serum-free, animal-component free reagents. You can benefit from our expertise and unique focus when looking to entrust a partner with your complete antibody production or to manage capacity bottlenecks with single projects.
Experience · 8 entries
All (8)
Investments (7)
Board (7)
2025
Investor & Board Observer
Aug 2025
For almost seven decades the Ackermann Group successfully continues to develop, manufacture and distribute premium solutions for a vast variety of surgical applications, primarily in the fields of open and minimally-invasive surgery, and also ligating and spinal implants. In addition to our strong brands, we stand behind an array of unique and highly sophisticated products as an OEM manufacturer and are proud of our global market leadership. True to our vision, INNOVATING TRADITION. It has always been our goal to provide our customers and healthcare professionals with industry-leading value proposition, through continuous innovation in our products and processes. We also believe that it is equally important not to lose sight of our roots, and to preserve the craftsmanship that has been perfected over generations as an established family business. This enables us to maintain a productive and sustainable home for our staff and improve clinical outcomes every single day in over 100 countries around the world. Our company is committed to manufacturing at the highest quality standards and all products produced conform to the requirements of the Medical Device Directive. Working to ensure our Quality Management system conforms to International Standard ISO13485:2016, SFDA, Medical Device Directive 93/43/EEC (CE), and Anvisa.
Investor & Board Observer
Jan 2025
ROTOP Pharmaka is a leading German pharmaceutical company that produces cGMP compliant radiopharmaceuticals for diagnostics and therapy in Nuclear Medicine and Molecular Imaging and distributes them in more than 30 countries worldwide. With almost 20 years of experience in the development, production, authorization and distribution of sterile kits for radiolabeled pharmaceuticals ROTOP continuously expands its product portfolio by developing new products and entering new strategic partnerships.
2023
Investor & Board Observer
Jul 2023
ESSERT Robotics is an expert in the field of automation of manual, industrial work processes based in Bruchsal. The company develops modular, highly standardized robot workstations and scalable production lines and continues to drive Industry 4.0 forward. With advanced robot systems and innovative solutions in mobile robotics, ESSERT Robotics helps medium-sized companies as well as well-known global players from all industries to increase their productivity and efficiency. Information on data processing in the context of visiting the LinkedIn page can be found in our data protection declaration at https://www.essert.com/privacy-policy/ .
Investor & Board Observer
Mar 2023
SIMULANDS was founded by a group of renowned clinicians, experienced engineers, entrepreneurs, and industry professionals in the field of Medical Devices and Structural Heart. We seek to revolutionize R&D and Education in the Structural Heart space. Simulators offer solutions that are more practical, cost-effective, and ethical versus traditional animal research practices. The 3R principles (replacement, reduction, and refinement) for more humane animal research are important guiding principles as our industry evolves. The latest technological advancements allow us to focus on what matters most – replicating procedure experiences that provide real tactile responses, and actual procedural imaging guidance with a true understanding of device performance. We believe the role of simulators should evolve from demo tools to complete educational, certification, and recertification platforms. SIMULANDS develops Human Grade platforms that are designed and validated according to all relevant ISO normative requirements. Our simulators are of clinical and technical equivalence to human cardiovascular systems and meet required benchmarks of various competent authorities, ethics committees and notified bodies (CE, FDA, MDR). We create simulators that are tailor-made, beautifully designed, simple to use and highly portable, and our joint training programs cater to a wide range of experience and knowledge levels. Questions? Support@Simulands.com
2022
Investor & Board Observer
May 2022
All primary care services. No waiting time. Always 595,- (NOK)
Show all 8 entries ↓
Investment activity
2019–2025 · 7 investments
2019120201202212023220252
Recent (last 2 years)Earlier